# Research Progress on Interleukin-6 in Screening and Prognosis of Patients with Non-small Cell Lung Cancer

## TL;DR

This paper reviews how interleukin-6 (IL-6) influences non-small cell lung cancer and its potential as a biomarker for screening and prognosis.

## Contribution

The paper highlights IL-6's role in NSCLC tumor progression and its emerging potential as a predictive biomarker for treatment outcomes.

## Key findings

- IL-6 plays a key role in NSCLC tumor microenvironment and immune evasion.
- IL-6 levels may predict adverse events in NSCLC treatment regimens.
- IL-6 shows potential as a biomarker for NSCLC screening and prognosis.

## Abstract

非小细胞肺癌（non-small cell lung cancer, NSCLC）作为肺癌的主要病理类型，其筛查与预后评估对于临床治疗方案的制定和患者生存率的提升具有重要意义，并且其发生和发展与炎症反应密切相关。白细胞介素-6（interleukin-6, IL-6）作为重要的炎症介质，在NSCLC的肿瘤微环境、免疫逃逸、肿瘤进展及治疗抵抗中发挥着关键作用。近年来的研究表明，IL-6不仅参与NSCLC的生物学行为，还可能作为潜在的筛查和预后生物标志物。本文综述了IL-6在NSCLC的筛查、治疗中可能出现的不良事件以及在NSCLC相关合并症中的应用。

Predictive effect of IL-6 on different treatment regimens